Chardan analyst Geulah Livshits lowered the firm’s price target on Achilles Therapeutics to $17 from $20 and keeps a Buy rating on the shares after the company presented data on its clonal neoantigen-reactive T cell platform from phase I/IIa trials CHIRON and THETIS in advanced NSCLC and melanoma, respectively, at ESMO I-O. The price target is based on probability-adjusted modeling of key franchises and "conservatively" incorporates dilution from a $15M equity raise in late 2022, Livshits noted.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ACHL:
- Achilles Therapeutics’ cNeT shows “encouraging” response in two cancer trials
- Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
- Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
- Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
- Achilles Therapeutics files to sell 5.54M ordinary shares for holders
